Halozyme Therapeutics - ENHANZE Licensing Revenue Drives new Records in Revenue and Earnings!
Reading Time: 1 minute
Business Drivers: The US biotech company Halozyme Therapeutics (HALO) specializes in products within the proprietary enzyme technology sector. The ENHANZE technology developed by Halozyme allows for the subcutaneous administration of biological and pharmaceutical active ingredients, which offers significant advantages over traditional intramuscular or intravenous drug administration. Among others, it is the ENHANZE technology that is used for the injectable combination product PHESGO developed by the Swiss pharmaceutical company Roche, which is...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
